ArticleFrontiers in oncology2022

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement.

Ning Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.